

1 Consensus development methods: Considerations for national and global frameworks
2 and policy development
3

4 Introduction

5 In this ever-changing world, key decisions have to be made in healthcare systems and policies often
6 under uncertain conditions or without complete objective evidence.¹⁻³ It is not uncommon for key
7 decisions in healthcare systems and policies to be made based on informal group decision making.²
8 However, various drawbacks of such an approach have been identified, including: particular
9 individuals are dominating discussion and decision making, pressures from powerful individuals and
10 the power imbalance of individuals in the group, more extreme decisions with individuals with
11 strong opinions, and complex issues remaining forgotten due to unstructured process.^{2, 5}

12 When decisions are made at national or international levels, the impact of such decisions become
13 even wider often affecting more stakeholders and sometimes entire populations. Decisions-making
14 in health systems and health policies at national and international levels would affect national and
15 global health, which might lead to inequality in health of population. In order to achieve transparent
16 and accountable decision-making process for optimising national and global health and achieving
17 equitable health access, consensus development methods (CDMs) can be adapted.

18 CDMs are commonly used for developing clinical guidelines for quality improvement of health care.^{5,}
19 ⁶ A complex process is involved in its consensus-based decision making.⁵ CDMs assist such complex
20 processes by offering a systematic approach to synthesising information and expert views.^{1, 7}

21 CDMs use a quantitative approach for synthesising qualitative data, aiming to achieve general
22 agreement, convergence of opinion, or resolving inconsistencies in scientific information around a
23 particular topic.^{2, 8, 9} The methods are widely used in the field of health, social care and wellbeing,¹⁰
24 including pharmacy practice,⁸ and are regularly applied for the development of clinical guidelines.
25 CDMs are officially used by the World Health Organisation for guideline development.¹¹

26 CDMs usually involve repetitive interactions with a group of participants to reach a general
27 agreement in the group. There are different types of CDMs available. The methods commonly
28 consist of the Nominal Group Technique (NGT), Delphi technique (DT), Consensus Development
29 Conference (CDC), RAND/UCLA appropriateness method (RAM). These differ in terms of anonymity,
30 the number of participants, the use of face-to-face meeting, and time frame.

31

32

33 Nominal Group Technique

34 The Nominal Group Technique (NGT) is a highly structured and controlled small group process
35 involving face-to-face group interaction.^{3, 8} The NGT was developed in the 1960s by Delbecq and
36 Van de Ven, originally developed in psychological studies, management science studies, and social
37 work studies.¹² The NGT has four main stages: silent generation, round robin, clarification and
38 voting/ranking.⁸

39 Silent generation is the first stage of NGT, where participants list ideas or issues related to the
40 particular topic silently and individually in a written format.¹² Round robin is the second stage, when
41 participants in turn state a single idea to the group one at a time in a 'round robin' fashion, then
42 continue to record one item from participants in sequence, until all group members have no more

1 ideas to state.^{8, 12} Third stage of the NGT is clarification where group members clarify, elaborate,
2 defend or dispute the ideas listed, using face-to-face focus group meeting.¹² During ranking, the last
3 stage, participants rank the preferences, agreement, or appropriateness depending on what the
4 NGT's aims are; ranking uses a structured questionnaire including Likert scales.^{2, 8, 12} If the pre-
5 defined level of consensus is not achieved, then the third and fourth stages are repeated until it
6 achieved. McMillan et al.⁸ proposes that the first two stages (i.e. silent generation and round robin)
7 can be replaced by literature reviews or exploratory surveys.

8 Throughout the stages, controlled interactions with small group of participants take place, with
9 normally 5 – 12 people, depending on the aims and topics of the study.^{1, 2} Cantril et al.³ suggested
10 that if a larger number of participants are required (i.e. more than 9 or 10 people), the participants
11 may require dividing into two or more parallel or sequential groups. Participants of the NGT are
12 'experts' of an investigating issue. This has an impact on the validity, credibility, reliability and
13 acceptability of the findings of the method.^{13, 14} Careful consideration should be given to group
14 composition, as different stakeholders tend to produce different ratings. However, within defined
15 specialist or professional categories, selecting particular individuals have little impact on the rating.¹⁵

16 The main advantages of the NGT include relatively quick outcomes to be obtained,⁸ a large number
17 of ideas to be generated,¹ and greater 'ownership' of the decision and tools developed by
18 participants,² which can affect how the decisions or tools implemented after the study. On the other
19 hand, some limitations include relatively small number of participants,² and the difficulty of setting
20 up face-to-face meetings.⁸

21 Delphi technique

22 The Delphi technique (DT) is an iterative survey technique for group decision making without face-
23 to-face interactions.³ The DT was introduced by the RAND Corporation in US in the 1950s, as a
24 means to forecasting the effects of atomic warfare in US.⁵ Since the DT was first introduced, the
25 method has been used in many academic fields, including science, technology, health, business,
26 communication, education and policy analysis.^{1, 7} The DT is applied within the pharmacy practice
27 field. McMillan et al.⁸ showcase examples which include scoping exercise of future practice and
28 education, developing criteria, indicators and definitions, and the more wide utilisation for clinical
29 guidelines development.

30 The DT process includes: collecting opinions/views on a particular issue, rating the agreement with
31 each item/statement, and re-rating the agreement with updated items/statements.⁷ All stages are
32 carried out using an anonymous questionnaire. This means participants never meet or interact in the
33 DT.⁵ Originally, the questionnaires are to be distributed by mail, but recently this has been replaced
34 largely by email or online questionnaire.⁸ The re-rating stage can be repeated as often as needed
35 depending on the degree of agreement reached from the second stage, or until a predetermined
36 number of rounds are completed.¹ In the first stage of the DT, opinions or views from experts are
37 usually collected by open ended questions,⁸ and analysed using content analysis approach.³ The
38 results of the first stage is summarised and converted into a list of statements/items in a
39 questionnaire to be distributed in the second phase.⁸ The degree of agreement is commonly
40 measured by Likert Scale,⁸ often with written feedback especially when the participant does not
41 agree with the item.¹ After reconsidering a group median of each item, participants will re-rate the
42 updated items again by Likert Scale.⁸ Some studies modified the DT process, particularly the first
43 stage, by replacing it with a literature review or qualitative study to explore more in-depth opinions.³

44 The DT allows for repetitive interactions with a large number of participants,⁷ which can range from
45 4 to 3000,¹³ and presents no geographical barriers for conducting the study since the techniques are

1 conducted remotely.² This flexibility, the option to have a large number of participants, and the
2 relatively low resources needed are significant advantages of the DT. Potential disadvantage may be
3 found in the fact that the participants do not engage with others nor do are they exposed to their
4 opinions and disagreements. Participants therefore do not change their opinions often; and it is
5 argued that agreement or consensus achieved is lower in level than that in NGT.²

6 Consensus Development Conference (CDC)

7 The consensus development conference (CDC) approach is thoroughly a face-to-face interactive
8 method to develop consensus among panel members at a public forum. CDCs were developed by
9 the National Institutes of Health (NIH) in US in 1977.⁵ CDCs are commonly used to evaluate and
10 disseminate health care technologies for clinical practices.¹⁶

11 The CDC involves a series of intensive face-to-face interactions of panel members (about 10 people).
12 Its process is more flexible compared to previous two methods, using iterative face-to-face meetings
13 of experts. A group of panel members are provided with evidence on a particular issue by a small
14 group of experts on the particular issue, and who are not involved in the decision-making process.¹⁷
15 The panel members will then ask questions to presenters. After clarifying all issues, the panel group
16 members will deliberate on the issue, directed by their chairperson to attempt to reach consensus.⁵

17 The main advantage of the CDC technique is to foster dialogue, debate and discussion.^{17, 18}
18 Furthermore, CDC method embeds a dissemination process of guidelines by holding a form of press
19 conference at the end of each round.¹⁶ However, significant drawback of the CDC includes expensive
20 study cost holding the public forum, which usually lasts more than two days. The time limitation to
21 hear the evidence from experts also is also at the same time a disadvantage of the method, as
22 presenters may not be able to cover all evidence related to the issue.¹⁷

23

24 RAND/UCLA appropriateness method (RAM)

25 The RAND/UCLA Appropriateness Method (RAM) is a hybrid method combining the elements of both
26 NGT and DT,¹⁵ developed by the RAND corporation and University of California Los Angeles (UCLA)
27 School of Medicine in the 1980s for a health services utilisation study, measuring the overuse and
28 underuse of medical and surgical procedures.¹⁹ RAM is commonly used in clinical practice for
29 developing guidelines. However, the method is also used in policy and organisational interventions.²⁰

30 RAM commonly involves 7-15 members of experts in the process.¹⁹ The RAM consists of 5 stages,
31 including (1) literature review to create a list of indicators for an intervention, (2) an expert panel to
32 rate the appropriateness of the intervention for each item measuring the degree of agreement by a
33 9-point Likert scale using an anonymous questionnaire, (3) face-to-face meeting of the expert panel,
34 (4) re-rating the appropriateness of updated items by Likert scale in an anonymous questionnaire,
35 and (5) categorising indicators as appropriate, inappropriate, or uncertain, based on the group
36 median rating.^{3, 15} Basic data analysis to determine agreement and disagreement is similar to NGT
37 and DT. However, the RAM uses more sophisticated analysis using the concept of interpercentile
38 Range (IPR) and Interpercentile Range Adjusted for Symmetry (IPRAS). This enables to avoid the
39 effect of different size of expert panel and to provide an in-depth analysis of 'disagreement' in
40 searching the appropriateness of items in a tool.¹⁹

41 These CDMs can be used to develop health and pharmacy policy tools and frameworks with a variety
42 of modifications and adaptations made over the decades. However, to the best of the authors'
43 knowledge, there is no review yet on the use of CDMs particularly in health systems and policy at
44 national and international levels. Understanding the different approaches, utilisations can support

1 researchers with ensuring rigour, validity, and transparency in the use of CDMs.. Therefore, this
2 paper aims to identify and review papers which have used CDMs in order to develop national or
3 international policy tools or framework in health field. The review identifies CDMs used in current
4 research, identify modifications and adaptations to traditional methods, and distil considerations
5 required for high level policy and framework development.

6

7 **Methods**

8 A narrative systematic review was conducted, following the PRISMA guidelines.

9 *Inclusion and exclusion criteria*

10 Eligible studies included those which used any of CDMs commonly used for developing a policy or
11 framework, or equivalent to framework (eg. tools or indicators) at a country or international level,
12 aiming to improve health system(s) or policy in health. Papers aimed to develop clinical guidelines
13 were excluded, as these are often developed following country specific developmental guidelines
14 (eg. National Institute for Health and Care Excellence in UK) or global WHO guideline,¹¹ and there are
15 intensive literature reviews on clinical guideline development (e.g. Black et al.⁶). Books, editorials,
16 and other sources reporting non-original research were excluded. Papers were excluded if they were
17 written in non-English.

18 *Search strategy*

19 Articles were searched in the electronic databases, including the EMBASE, PsycINFO, and PubMed as
20 of 3rd November 2020. The search did not limit the publication years. The search terms 'consensus
21 development' and 'framework', which were crosschecked with 'health system' OR 'health policy'.
22 The exact strategy used was [(consensus development) AND (framework) AND ((health system) OR
23 (health policy))]. All retrieved citation data were entered into EndNote X9 (Clarivate Analytics,
24 Philadelphia, US), and cleaned to remove duplicated papers.

25 The authors applied the inclusion and exclusion criteria to independently examine the titles and
26 abstracts of the original articles. A list of eligible articles was discussed including any divergence
27 occurred between both authors until the final list was agreed.

28 *Data extraction and synthesis*

29 A data extraction table was prepared in Microsoft Excel sheet and agreed by both authors. The
30 primary investigator (NA) extracted the data, which were reviewed by LRB. Collected data were
31 narratively synthesised using content analysis in terms of the use of CDMs and the way the methods
32 were modified according to the study settings.

33 **Results**

34 *Screening and selection of studies*

35 The screening process following the PRISMA guidelines is depicted in Figure 1. The searches in
36 EMBASE, PsycINFO, and PubMed identified 70 different titles. The titles and abstracts were reviewed
37 for inclusion and exclusion criteria, which excluded 34 papers. The remaining 37 papers were
38 assessed for their eligibility by reviewing full-text articles. This identified an additional eligible article
39 from reference lists of the reviewed papers, and further excluded 11 articles in alignment with the
40 inclusion and exclusion criteria. In total, 26 articles were included in the final analysis.

1 Table 1 summarises collected data from each study. Thirteen studies developed frameworks at
2 international levels or engaged with multiple countries.²¹⁻³³ Other remaining studies were conducted
3 at a national level, including India,³⁴ Iran,^{35, 36} The Netherlands,³⁷ Canada,³⁸ Libya,³⁹ US,⁴⁰⁻⁴³ and
4 Spain.⁴⁴ Out of 13 international studies, 4 papers^{28, 30-32} related to the same academic society for
5 rheumatology, carrying out at the Outcome Measures in Rheumatology (OMERACT) activities. The
6 review identified that a wide range of frameworks or tools were developed using CDMs. The
7 purposes of frameworks or tools include improving health services, health systems, health policies,
8 and workforce development.

9 The papers related to consensus development in health policy and system field published more
10 recently in a last decade. Nineteen papers (73.1%) were published between 2010 and 2020,<sup>21-26, 28, 30-
11 36, 38, 39, 41-43</sup> 6 papers (23.1%) in 2000s,^{27, 29, 37, 40, 44, 45} and 1 (3.8%) in 1998,⁴⁶ although no restriction
12 was made for publication years in the literature search. Considering the CDMs developed in 1950s to
13 1960s, it has taken around 50 years to populate the use of CDMs in health policy and system
14 research field.

15 The search identified that over 60% of studies did not apply typical consensus development
16 methods, but were stated as consensus meetings. Sixteen studies (61.5%)^{21-24, 26-28, 30-35, 37, 39, 42}
17 claimed the use of consensus meeting as a main or part of their process, 12 studies (46.2%)<sup>21, 24, 25, 29,
18 30, 35, 36, 38, 40, 41, 45, 46</sup> used the DT as a main or part of their process, and 4 studies (15.4%)^{36, 40, 44, 46}
19 applied NGT as a main or part of their methods, and 1 study (3.8%)⁴³ claimed iterative feedbacks as
20 their consensus method. The review illustrated a wide range of modification of methods, which are
21 either non-use of typical CDM or combining different methods to compensate weakness of used
22 methods. The most common combination of different methods was a combined use of DT and some
23 form of face-to-face meetings (CM or NGT).^{21, 24, 30, 36, 40, 46} No paper described reasons for non-use of
24 formal CDM or combination of methods. However, this review indicates the formal CDMs may not
25 fitting in developing national or international level framework or tools in health system and health
26 policy areas.

27 Many studies did not state the numbers of consensus panel members (9 studies, 34.6%)<sup>22, 23, 27, 28, 32,
28 34, 36, 42, 43</sup> nor consensus thresholds (15 studies, 57.7%).^{21-23, 26-28, 30-34, 36, 37, 39, 44} Among the studies
29 claimed the number of panel members, there was a varying number of members engaged from 4 to
30 500, depending on the purpose of the tool developed and audience whether national or
31 international levels. Reporting the number of consensus panel members and consensus threshold
32 have an impact on the quality of the report and affect the rigour and value of decisions made.

33 Discussion

34 This review is first of its kind focusing the use of CDMs for developing frameworks and tools in health
35 systems and policy at country or international levels. A number of variations of consensus
36 development methods have been developed since its first development in 1950s and 1960s, and the
37 use of methods over the last a half century. CDMs have been adapted for use in healthcare field,
38 often for clinical guideline development or health technology assessment. This present review
39 focused on the use of consensus development approach in health policy and system improvement
40 outside of clinical guideline development. The review identified a wide range of modifications of
41 CDMs, and many did not follow any of existing consensus development methods. This is not
42 consistent with the use of CDMs in creating clinical guidelines where intensive reviews and
43 guidelines for formal steps of CDMs were developed. Humphrey-Murto et al.¹ criticise that a lack of
44 standardization in definitions of consensus, use of methods, and reporting of these methods would
45 result in less certain the level of rigour or value of decisions made.

1 However, high-level consensus in national and international settings often encounter challenges of
2 geographical issues of panel members and time commitment of members with different countries
3 when it comes to international framework development. Considering these challenges, it is
4 understandable to have consensus development processes in academic conference settings and
5 combine some methods to utilise opportunities for meetings at conferences and other processes
6 conducted at online platforms as the review identified. The authors experienced consensus
7 development processes at national and international levels, in order to develop national and
8 international policy, framework and tools in pharmacy field.

9 For example, the International Pharmaceutical Federation (FIP) has recently launched a global list of
10 FIP Development Goals as a key resource for transforming the pharmacy profession over the next
11 decade globally, regionally and nationally. For the goals to be globally relevant and to increase
12 uptake, it was essential that the development approach was based on consensus; but engaging
13 global experts and stakeholders required a practice approach to consensus developed that
14 combined elements of the traditional CDMs. An extensive process of consultation built on the
15 methodology used in the development of the Pharmaceutical Workforce Development Goals
16 (PWDGs) and adapted to develop the practice and science elements in the new goals. FIP experts,
17 members, partners and stakeholders have all taken part in this work to ensure that the goals are
18 relevant, measurable and achievable. The development process included a consultation with the FIP
19 Council in 2019; the Council is FIP's highest organ which includes all national pharmaceutical
20 associations (member organisations) and national pharmaceutical scientific associations
21 (predominantly scientific member organisations). This element of the process adopted and adapted
22 the CDC method by conducting a face to face meeting during a global conference. Afterwards, a
23 cross-FIP Internal Reference Group was commissioned to provide feedback and input into the draft
24 Goals; the Group included representatives from FIP Boards of practice and science, FIP Education as
25 well as the FIP Young Pharmacists Group. The Internal Reference Group was engaged in the
26 consultation using Delphi technique approaches.

27 A lack of consensus criteria reporting in papers was identified throughout the review. Scott and
28 Black⁴⁸ showed that differences in consensus definitions lead to the nature and level of consensus
29 that panel would reach. For achieving transparent and rigour consensus decisions in health,
30 reporting the consensus threshold and criteria is essential. This indicates the need of rigorous
31 planning of the consensus development process at national and international levels. Especially any
32 decisions made in health system and policy affect national and global health. The researchers and
33 policy makers need to be aware of the consensus development methods for better decision making
34 process. For that, creating a guidance of CDMs to develop national/international frameworks or
35 tools in health system and policy would be warranted.

36 It is important to note a limitation of the review. A literature search in the review was only carried
37 out with limited literature database (i.e., PubMed and EMBASE) due to the resource limited to
38 authors. A narrative systematic review limits evaluation of selected articles for validity. Considering
39 the nature of the methods developed outside of health field, there may be more literature using
40 consensus development methods in health system and policy development. Having identified the
41 variety of modifications in consensus development methods in health system and policy
42 development, the development of practical standards for CDMs would be warranted.

43

1 Conclusion

2 This review summarised the use of consensus development methods in health system and policy
3 development. The review identified a wide range of variations in the selection, use and application
4 of the methods in the field. Some elements of consensus development process (i.e., the number of
5 panel members and consensus threshold) were not reported in all papers, which addressed the
6 issues in the quality of reporting with the use of consensus development methods. For better
7 utilisation and application of the consensus development methods in health system and policy
8 development, some standardisation of the methods and reporting would be warranted while
9 allowing for the necessary pragmatic adaptations needed by researchers.

10

11 Declarations

12 *Ethics*

13 A present literature review does not require ethical clearance.

14 *Declaration of interest*

15 None

16 *Author contributions*

17 NA: concept development, data collection, analysis and original draft writing

18 LRB: review for data collection and original draft, and edit

19

20 References

- 21 1. Humphrey-Murto, S., Varpio, L., Gonsalves, C., and Wood, T.J., Using consensus group
22 methods such as Delphi and Nominal Group in medical education research. *Medical Teacher*,
23 2017;39:14-19.
- 24 2. Black, N., *Chapter 12: Consensus development methods*, in *Qualitative Research in Health*
25 *Care - 3rd ed.*, C. Pope and N. Mays, Editors. Blackwell Publishing Ltd: Oxford; 2006.
- 26 3. Cantrill, J.A., Sibbald, B., and Buetow, S., The Delphi and nominal group techniques in health
27 services research. *International Journal of Pharmacy Practice*, 1996;4:67-74.
- 28 4. Jennings, B., *Counsel and Consensus: Norms of Argument in Health Policy*, in *The*
29 *argumentative turn in policy analysis and planning*, F. Fisher and J. Forester, Editors. Duke
30 University Press: London; 1993.
- 31 5. Murphy, M.K., Black, N.A., Lamping, D.L., McKee, C.M., Sanderson, C.F., Askham, J., and
32 Marteau, T., Consensus development methods, and their use in clinical guideline
33 development. *Health Technology Assessment*, 1998;2:i-iv, 1-88.
- 34 6. Black, N., Murphy, D.M., Lamping, D., Mckee, M., Sanderson, C., Askham, J., and Marteau, T.,
35 Consensus development methods: a review of best practice in creating clinical guidelines.
36 *Journal of Health Services Research & Policy*, 1999;4:236-48.
- 37 7. Jones, J. and Hunter, D., Qualitative Research: Consensus methods for medical and health
38 services research. *BMJ*, 1995;311:376.
- 39 8. McMillan, S.S., King, M., and Tully, M.P., How to use the nominal group and Delphi
40 techniques. *International Journal of Clinical Pharmacy*, 2016;38:655-662.
- 41 9. Tammela, O., Applications of consensus methods in the improvement of care of paediatric
42 patients: a step forward from a 'good guess'. *Acta Paediatrica*, 2013;102:111-115.

- 1 10. Guzyz, D., Dickson-Swift, V., Kenny, A., and Threlkeld, G., Gadamerian philosophical
2 hermeneutics as a useful methodological framework for the Delphi technique. *International*
3 *Journal of Qualitative Studies on Health and Well-being*, 2015;10:26291.
- 4 11. World Health Organization, *WHO Handbook for Guideline Development - 2nd edition*.
5 Geneva: World Health Organization; 2014.
- 6 12. Van de Ven, A.H. and Delbecq, A.L., The nominal group as a research instrument for
7 exploratory health studies. *American journal of public health*, 1972;62:337-342.
- 8 13. Campbell, S.M. and Cantrill, J.A., Consensus methods in prescribing research. *Journal of*
9 *Clinical Pharmacy and Therapeutics*, 2001;26:5-14.
- 10 14. Grimshaw, J. and Russell, I., Achieving health gain through clinical guidelines. I: Developing
11 scientifically valid guidelines. *Quality in health care : QHC*, 1993;2:243-248.
- 12 15. Hutchings, A. and Raine, R., A systematic review of factors affecting the judgments produced
13 by formal consensus development methods in health care. *Journal of Health Services*
14 *Research & Policy*, 2006;11:172-9.
- 15 16. Fink, A., Kosecoff, J., Chassin, M., and Brook, R.H., Consensus Methods: Characteristics and
16 Guidelines for Use. *American journal of public health*, 1984;74:979-983.
- 17 17. James, D. and Warren-Forward, H., Research methods for formal consensus development.
18 *Nurse Researcher*, 2015;22:35-40.
- 19 18. Halcomb, E., Davidson, P., and Hardaker, L., Using the consensus development conference
20 method in healthcare research. *Nurse Researcher*, 2008;16:56-71.
- 21 19. Fitch, K., Bernstein, S.J., Aguilar, M.D., Burnand, B., LaCalle, J.R., Lazaro, P., van het Loo, M.,
22 McDonnell, J., Vader, J.P., and Kahan, J.P., *The RAND/UCLA appropriateness method user's*
23 *manual*. Santa Monica, CA: RAND; 2001.
- 24 20. Campbell, J.L., Fletcher, E., Abel, G., Anderson, R., Chilvers, R., Dean, S.G., Richards, S.H.,
25 Sansom, A., Terry, R., Aylward, A., Fitzner, G., Gomez-Cano, M., Long, L., Mustafee, N.,
26 Robinson, S., Smart, P.A., Warren, F.C., Welsman, J., and Salisbury, C., Policies and strategies
27 to retain and support the return of experienced GPs in direct patient care: the ReGROUP
28 mixed-methods study. *Hearth Services and Delivery Research*, 2019;7.
- 29 21. Calvert, M., Kyte, D., Mercieca-Bebber, R., Slade, A., Chan, A.-W., King, M.T., and the SPIRIT-
30 PRO Group, Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols:
31 The SPIRIT-PRO Extension. *JAMA*, 2018;319:483-494.
- 32 22. Cornel, M.C., Rigger, T., Weinreich, S.S., Burgard, P., Hoffmann, G.F., Lindner, M., Gerard
33 Loeber, J., Rupp, K., Taruscio, D., and Vittozzi, L., A framework to start the debate on
34 neonatal screening policies in the EU: an Expert Opinion Document. *European Journal of*
35 *Human Genetics*, 2014;22:12-17.
- 36 23. Salvador-Carulla, L., Reed, G.M., Vaez-Azizi, L.M., Cooper, S.-A., Leal, R.M., Bertelli, M.,
37 Adnams, C., Cooray, S., Deb, S., Dirani, L.A., Girimaji, S.C., Katz, G., Kwok, H., Luckasson, R.,
38 Simeonsson, R., Walsh, C., Munir, K., and Saxena, S., Intellectual developmental disorders:
39 towards a new name, definition and framework for "mental retardation/intellectual
40 disability" in ICD-11. *World Psychiatry*, 2011;10:175-180.
- 41 24. Forrest, C.B., Chesley Jr, F.D., Tregear, M.L., and Mistry, K.B., Development of the Learning
42 Health System Researcher Core Competencies. *Health Services Research*, 2018;53:2615-
43 2632.
- 44 25. Balakrishnan, K., Sidell, D.R., Bauman, N.M., Bellia-Munzon, G.F., Boesch, R.P., Bromwich,
45 M., Cofer, S.A., Daines, C., de Alarcon, A., Garabedian, N., Hart, C.K., Ida, J.B., Leboulanger,
46 N., Manning, P.B., Mehta, D.K., Monnier, P., Myer, C.M., Prager, J.D., Preciado, D., Propst,
47 E.J., Rahbar, R., Russell, J., Rutter, M.J., Thierry, B., Thompson, D.M., Torre, M., Varela, P.,
48 Vijayasekaran, S., White, D.R., Wineland, A.M., Wood, R.E., Wootten, C.T., Zur, K., and
49 Cotton, R.T., Outcome measures for pediatric laryngotracheal reconstruction: International
50 consensus statement. *Laryngoscope*, 2018;129:244-255.


- 1 26. Dreesens, D., Stiggelbout, A., Agoritsas, T., Elwyn, G., Flottorp, S., Grimshaw, J., Kremer, L.,
2 Santesso, N., Stacey, D., Treweek, S., Armstrong, M., Gagliardi, A., Hill, S., Légaré, F., Ryan, R.,
3 Vandvik, P., and van der Weijden, T., A conceptual framework for patient-directed
4 knowledge tools to support patient-centred care: Results from an evidence-informed
5 consensus meeting. *Patient Education and Counseling*, 2019;102:1898-1904.
- 6 27. Garrison, L.P.J., Neumann, P.J., Erickson, P., Marshall, D., and Mullins, C.D., Using real-world
7 data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
8 *Value in Health*, 2007;10:326-335.
- 9 28. Kirwan, J.R., Boers, M., Hewlett, S., Beaton, D., Bingham, C.O., Choy, E., Conaghan, P.G.,
10 D'Agostino, M.-A., Dougados, M., Furst, D.E., Guillemin, F., Gossec, L., van der Heijde, D.M.,
11 Kloppenburg, M., Kvien, T.K., Landewé, R.B.M., Mackie, S.L., Matteson, E.L., Mease, P.J.,
12 Merkel, P.A., Ostergaard, M., Sacketkoo, L.A., Simon, L., Singh, J.A., Strand, V., and Tugwell,
13 P., Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. *The*
14 *Journal of Rheumatology*, 2014;41:994.
- 15 29. Mattke, S., Epstein, A.M., and Leatherman, S., The OECD Health Care Quality Indicators
16 Project: history and background. *International Journal for Quality in Health Care*, 2006;18:1-
17 4.
- 18 30. Boers, M., Idzerda, L., Kirwan, J.R., Beaton, D., Escorpizo, R., Boonen, A., Magasi, S., Sinha, I.,
19 Stucki, G., and Tugwell, P., Toward a Generalized Framework of Core Measurement Areas in
20 Clinical Trials: A Position Paper for OMERACT 11. *The Journal of Rheumatology*, 2014;41:978.
- 21 31. Kirwan, J.R., Bartlett, S.J., Beaton, D.E., Boers, M., Bosworth, A., Brooks, P.M., Choy, E., de
22 Wit, M., Guillemin, F., Hewlett, S., Kvien, T.K., Landewé, R.B., Leong, A.L., Lyddiatt, A., March,
23 L., May, J., Montie, P.L., Nikai, E., Richards, P., Voshaar, M.M.J.H., Smeets, W., Strand, V.,
24 Tugwell, P., and Gossec, L., Updating the OMERACT Filter: Implications for Patient-reported
25 Outcomes. *The Journal of Rheumatology*, 2014;41:1011.
- 26 32. D'Agostino, M.A., Boers, M., Kirwan, J., van der Heijde, D., Østergaard, M., Schett, G.,
27 Landewé, R.B., Maksymowych, W.P., Naredo, E., Dougados, M., Iagnocco, A., Bingham,
28 C.O.r., Brooks, P.M., Beaton, D.E., Gandjbakhch, F., Gossec, L., Guillemin, F., Hewlett, S.E.,
29 Kloppenburg, M., March, L., Mease, P.J., Moller, I., Simon, L.S., Singh, J.A., Strand, V.,
30 Wakefield, R.J., Wells, G.A., Tugwell, P., and Conaghan, P.G., Updating the OMERACT filter:
31 implications for imaging and soluble biomarkers. *Journal of Rheumatology*, 2014;41:1016-24.
- 32 33. Kumanyika, S., Taylor, W.C., Grier, S.A., Lassiter, V., Lancaster, K.J., Morssink, C.B., and
33 Renzaho, A.M.N., Community energy balance: A framework for contextualizing cultural
34 influences on high risk of obesity in ethnic minority populations. *Preventive Medicine*,
35 2012;55:371-381.
- 36 34. Lalitha, A.V., Fassl, B., Gist, R.E., Shah, B.R., Chawla, N., Singh, A., Baranawal, A., Shamarao,
37 S., Vanaki, R., Mahajan, P., Patel, R., Chauhan, V., Batra, P., Saha, A., Galwankar, S., and
38 Soans, S., 2019 WACEM - Academic College of Emergency Experts Consensus
39 Recommendations on Admission Criteria to Pediatric Intensive Care Unit from the
40 Emergency Departments in India. *Journal of Emergencies, Trauma, and Shock*, 2019;12:155-
41 162.
- 42 35. Fazaeli, S., Ahmadi, M., Rashidian, A., and Sadoughi, F., A framework of a health system
43 responsiveness assessment information system for Iran. *Iranian Red Crescent Medical*
44 *Journal*, 2014;16:e17820.
- 45 36. Ardalan, A., Rajaei, M.H., Masoumi, G., Azin, A., Zonoobi, V., Sarvar, M., Vaskoei Eshkevari,
46 K., Ahmadnezhad, E., and Jafari, G., 2012-2025 Roadmap of I.R.Iran's Disaster Health
47 Management. *PLoS currents*, 2012;4:e4f93005fbc34-e4f93005fbc34.
- 48 37. ten Asbroek, A.H.A., Arah, O.A., Geelhoed, J., Custers, T., Delnoij, D.M., and Klazinga, N.S.,
49 Developing a national performance indicator framework for the Dutch health system.
50 *International Journal for Quality in Health Care*, 2004;16:i65-i71.

- 1 38. Rae, C.S., Pole, J.D., Gupta, S., Digout, C., Szwajcer, D., Flanders, A., Srikanthan, A.,
2 Hammond, C., Schacter, B., Barr, R.D., and Rogers, P.C., Development of System
3 Performance Indicators for Adolescent and Young Adult Cancer Care and Control in Canada.
4 *Value in Health*, 2020;23:74-88.
- 5 39. El Oakley, R.M., Ghrew, M.H., Aboutwerat, A.A., Alageli, N.A., Neami, K.A., Kerwat, R.M.,
6 Elfituri, A.A., Ziglam, H.M., Saifenasser, A.M., Bahron, A.M., Aburawi, E.H., Sagar, S.A.,
7 Tajoury, A.E., and Benamer, H.T.S., Consultation on the Libyan health systems: towards
8 patient-centred services. *Libyan Journal of Medicine*, 2013;8:20233.
- 9 40. Hermann, R.C., Palmer, H., Leff, S., Shwartz, M., Provost, S., Chan, J., Chiu, W.T., and
10 Lagodmos, G., Achieving Consensus Across Diverse Stakeholders on Quality Measures for
11 Mental Healthcare. *Medical Care*, 2004;42.
- 12 41. Spyropoulos, A.C., Viscusi, A., Singhal, N., Gilleylen, J., Kouides, P., Howard, M., Rudd, K.,
13 Ansell, J., and Triller, D.M., Features of electronic health records necessary for the delivery of
14 optimized anticoagulant therapy: consensus of the EHR Task Force of the New York State
15 Anticoagulation Coalition. *Annals of Pharmacotherapy*, 2015;49:113-124.
- 16 42. Leone, F.T., Carlsen, K.-H., Chooljian, D., Crotty Alexander, L.E., Detterbeck, F.C., Eakin, M.N.,
17 Evers-Casey, S., Farber, H.J., Folan, P., Kathuria, H., Latzka, K., McDermott, S., McGrath-
18 Morrow, S., Moazed, F., Munzer, A., Neptune, E., Pakhale, S., Sachs, D.P.L., Samet, J., Sufian,
19 B., and Upson, D., Recommendations for the Appropriate Structure, Communication, and
20 Investigation of Tobacco Harm Reduction Claims. An Official American Thoracic Society
21 Policy Statement. *American Journal of Respiratory and Critical Care Medicine*, 2018;198:e90-
22 e105.
- 23 43. Mazzone, P., Powell, C.A., Arenberg, D., Bach, P., Detterbeck, F., Gould, M.K., Jaklitsch, M.T.,
24 Jett, J., Naidich, D., Vachani, A., Wiener, R.S., and Silvestri, G., Components Necessary for
25 High-Quality Lung Cancer Screening: American College of Chest Physicians and American
26 Thoracic Society Policy Statement. *CHEST*, 2015;147:295-303.
- 27 44. Grandes, G., Sanchez, A., Cortada, J.M., Balague, L., Calderon, C., Arrazola, A., Vergara, I.,
28 Millan, E.S., and Prescribe Vida Saludable group, Is integration of healthy lifestyle promotion
29 into primary care feasible? Discussion and consensus sessions between clinicians and
30 researchers. *BMC Health Services Research*, 2008;8:213.
- 31 45. Hughes, R., Competencies for effective public health nutrition practice: a developing
32 consensus. *Public Health Nutrition*, 2004;7:683-691.
- 33 46. Nijs, H.G., Bleeker, J.K., van Der Waal, M.A., and Casparie, A.F., Need for consensus
34 development in prehospital emergency medicine: effect of an expert panel approach.
35 *European Journal of Emergency Medicine*, 1998;5:329-34.
- 36 47. Schünemann, H.J., Wiercioch, W., Etzeandia, I., Falavigna, M., Santesso, N., Mustafa, R.,
37 Ventresca, M., Brignardello-Petersen, R., Laisaar, K.-T., Kowalski, S., Baldeh, T., Zhang, Y.,
38 Raid, U., Neumann, I., Norris, S.L., Thornton, J., Harbour, R., Treweek, S., Guyatt, G., Alonso-
39 Coello, P., Reinap, M., Brožek, J., Oxman, A., and Akl, E.A., Guidelines 2.0: systematic
40 development of a comprehensive checklist for a successful guideline enterprise. *Canadian
41 Medical Association Journal*, 2014;186:E123.
- 42 48. Scott, E.A. and Black, N., When does consensus exist in expert panels? *Journal of Public
43 Health Medicine*, 1991;13:35-39.

44

45 Figure 1: PRISMA flowchart

Identification
 Screening
 Eligibility
 Included



1
 2

RSAP ACCEPT

Table 1: Consensus development studies in health policy and system field

Authors (year)	Country	Framework/policy that consensus developed upon	Consensus development method	No. of panel members	Consensus threshold	Method modification
Lalitha et al. (2019) ³⁴	India	Admission criteria on paediatric intensive care unit in India	CM	Not stated	Not stated	<ul style="list-style-type: none"> Consensus was not developed in the CM. Full taskforce team discussed, and consensus developed on the refined draft framework from CM
Calvert et al. (2018) ²¹	International	SPIRIT-Patient Reported Outcomes (PRO) Extension	DT and CM	DT: n=99 CM: n=29	Not stated	<ul style="list-style-type: none"> DT – 2 rounds of online surveys CM – 2-day face-to-face meeting Final consultation through 3-week period with all attendees from DT and CM Consensus/final agreement by the SPIRIT-PRO group
Fazaeli et al. (2014) ³⁵	Iran	A framework of a health system responsiveness assessment information system	DT and CM	DT: n=25	Components with $\geq 75\%$ agreement were used for the secondary framework. Components with 50 to 75% agreement were entered into the second round of DT. Items with $< 50\%$ agreement were excluded.	<ul style="list-style-type: none"> DT – 2 rounds of surveys with 3-point Likert scale (no information on distribution method) CM – face-to-face meeting by panel members to discuss results to reach consensus
Cornel et al. (2014) ²²	International (EU)	A framework on newborn screening implementation	CM	Not stated	Not stated	<ul style="list-style-type: none"> Consensus was not developed in the CM. Consultation by email and face-to-face meeting with panel members Final document was endorsed by the Boards of the International Society.

Salvador-Carulla et al. (2011) ²³	International	Classification of intellectual disabilities in ICD-11	CM	Not stated	Not stated	<ul style="list-style-type: none"> A series of meetings – 3 face-to-face meetings, 7 teleconferences, and electronic exchanges
Ten Asbroek et al. (2004) ³⁷	The Netherlands	A national performance indicator framework for the Dutch health system	CM	38	Not stated	<ul style="list-style-type: none"> A series of meetings – not stated the frequency and delivery of the meetings
Rae et al. (2020) ³⁸	Canada	System performance indicators for adolescent and young adult cancer care and control	DT	10	<p>Survey 1 - indicator eliminated if <70% of group scored the indicator as a 3</p> <p>Survey 2 - indicator eliminated if <60% of group scored the indicator as a 3</p> <p>Final consensus - endorsed by $\geq 80\%$ of group in Round 1 and 3</p>	<ul style="list-style-type: none"> DT – 3 rounds of surveys (no information on distribution method)
Forrest et al. (2018) ²⁴	International	A list of core competencies for learning health system researchers	DT and CM	19	<p>CM consensus: Not stated</p> <p>DT consensus: Competencies with a median of at least 7 and $\geq 75\%$ of panel members rating between 7 and 9 were evaluated for retention</p>	<ul style="list-style-type: none"> CM – 2 face-to-face expert panel meeting, rating competencies with 5-point Likert scale DT – 1 round of a modified process with 9-point Likert scale (no information on distribution method) CM – final face-to-face expert panel meeting
Balakrishnan et al. (2018) ²⁵	International	Outcome measures for paediatric laryngotracheal reconstruction	DT	40	Consensus for mean rating ≥ 7 , with ≤ 1 response ≥ 2 points away from mean	<ul style="list-style-type: none"> 2 different rounds of surveys at different levels of important to include (with 9-point Likert scale)

					Near consensus for mean rating ≥ 6.5 , with ≤ 2 response ≥ 2 points away from mean	
Dreesens et al. (2019) ²⁶	International	A conceptual framework for patient-directed knowledge tools to support patient-centred care	CM	15 (9 attended in person, 4 attended through teleconference, and 2 participated via email)	Not stated	<ul style="list-style-type: none"> 2-day face-to-face consensus meeting with international experts
Garrison et al. (2007) ²⁷	International	A framework to assist health-care decision-makers in dealing with Real-world data	CM	Not stated	Not stated	<ul style="list-style-type: none"> Face-to-face meetings and electronic exchange via email with Taskforce members and public consultation from the membership of the ISPOR
Kirwan et al. (2014) ²⁸		Outcome Measures in Rheumatology (OMERACT) Filters: core outcome sets	CM	Not stated	Not stated	<ul style="list-style-type: none"> Face-to-face meetings using breakout small group discussion at conference got for discussion and a final plenary voting
Mattke et al. (2006) ²⁹	International (OECD)	Health care quality indicators	DT	4 expert panels (the number of panel members of each panel was not stated)	Retain measures with high ratings (≥ 7) on both relevance and soundness, and also measures with intermediate scores on those dimensions if data collection considered to be feasible	<ul style="list-style-type: none"> A modified DT – evaluate the relevance and scientific soundness of identified indicators with 9-point Likert scale (no statement on the frequency of rounds)
El Oakley et al. (2013) ³⁹	Libya	Recommendations mapping a modern health systems for the 21 st century	CM	500	Not stated	<ul style="list-style-type: none"> A half-day conference session, in which potential solutions and priorities for change were identified – where consensus

						achieved, included in proposed recommendations
Boers et al. (2014) ³⁰	International	A framework of core measurement areas in clinical trials for OMERACT 11	DT and CM	CM – 18 DT - 262	Not stated	<ul style="list-style-type: none"> • CM – held at conference for structured discussion • DT – invited 2293 people – a total of 262 returned, indicating broad agreement
Kirwan et al. (2014) ³¹	International	A framework for identifying the relevant core outcomes universal to all studies of the effects of intervention effects	CM	>115	Not stated	<ul style="list-style-type: none"> • Group discussions with small breakout groups at conference
Hermann et al. (2004) ⁴⁰	US	A core set of quality measures for mental health and substance-related care	DT and NGT	12	Meaningfulness of 3 or less with dispersion of ≤ 0.8 Feasibility of ≤ 6 with dispersion ≤ 0.9 The highest-rated measure in that category was added to the core set.	<ul style="list-style-type: none"> • A modified DT – 2 rounds of surveys, assessing with 3 scales of meaningfulness, 3 scales of feasibility and 1 scale for overall agreement of inclusion, using 9-point Likert scale • Face-to-face meeting – discussing the results of 1st round of DT on measures with overall scores of 6 or less and significant dispersion
Grandes et al. (2008) ⁴⁴	Spain	Factors in the Basque Health System hindering/facilitating the integration of healthy lifestyle promotion in primary health care setting	NGT	12	Not stated	<ul style="list-style-type: none"> • 5 structured meetings for discussion • A draft circulation to verify validity of document
D'Agostino et al. (2014) ³²	International	An imaging or biochemical measurement	CM	Not stated	Not stated	<ul style="list-style-type: none"> • 3 disease-related groups further divided into small breakout

		instrument in OMERACT Filter				<ul style="list-style-type: none"> groups to discuss and propose new hierarchical structure Each discussion group reported to its main plenary session of all participants
Spyropoulos et al. (2015) ⁴¹	US	A list of electronic health records features clinically necessary to delivery optimized anticoagulation management	DT	12	No more than one reviewer expressing opposition to any recommended feature	<ul style="list-style-type: none"> Electronic circulation of draft logic and technical guidance among taskforce members (n = 150) 1 round of DT – assessing a clinical necessity using 5-point Likert Scale
Leone et al. (2018) ⁴²	US	Standards of practice in making tobacco harm reduction claims	CM	Not stated	Unanimous approval	<ul style="list-style-type: none"> Online and face-to-face meetings, and electronic circulation of successive drafts
Kumanyika et al. (2012) ³³	International	A visual and narrative framework for community-level interventions for obesity	CM	6	Not stated	<ul style="list-style-type: none"> A 2-day session and literature review for preliminary framework 2-year iterative consultation
Nijs et al. (1998) ⁴⁶	The Netherlands and Belgium	Agreement on prehospital emergency medicine care	DT and NGT	7	Multiple rater kappa values (a kappa value of 1 denotes perfect agreement, corrected for chance-expected agreement. A value of 0 denotes that observed agreement equals chance-expected agreement. A value below 0 denotes that observed agreement is even less than chance-expected agreement)	<ul style="list-style-type: none"> A modified DT – 2 rounds of posting process assessing the need of cares A modified NGT – discussing the lowest agreement case and re-rating

Mazzone et al. (2015) ⁴³	US	Policy statements on the components necessary for high-quality lung cancer screening	Iterative feedback	Not stated	Unanimous approval	<ul style="list-style-type: none"> Iterative written and verbal feedback of committee members on 2 quality metrics assessing validity, feasibility and relevance
Ardalan et al. (2012) ³⁶	Iran	2012-2025 roadmap of Disaster Health Management	NGT and DT	Not stated	Not stated	<ul style="list-style-type: none"> NGT – discussing and assessing necessity of items (no information of specific process) DT – No information of the frequency and distribution method
Hughes (2004) ⁴⁵	International (EU, US, AUS)	Competencies for effective public health nutrition practice	DT	20	Consensus cut-offs of ≥80% agreement rated essential in Rounds 1 and 3.	<ul style="list-style-type: none"> A modified DT – 3 rounds of surveys (via email) with 3-point rating scales assessing the relevance

*Abbreviation for consensus development method: Consensus meeting (CM), Delphi Technique (DT), Nominal Group Technique (NGT), Consensus Development Conference (CDC).